180 Life Sciences Corp.ATNF

Market cap
$12.56M
P/E ratio
Dec 31,
2017
Dec 31,
2018
Dec 31,
2019
Dec 31,
2020
Dec 31,
2021
Dec 31,
2022
Net loss123,7641-91,300-10,884,058-20,324,648-38,726,259
Stock-based compensation---1--
Shares issued for services----2331,591
Amortization of stock options and restricted stock units----33
Impairment of goodwill-----34
Impairment of IP R&D assets-----3
Amortization of intangibles----109,947109,004
Gain on settlement of liabilities, net----926,829-
Loss on extinguishment of convertible note payable----9,737-
Deferred tax liability----24,803942,749
Offering costs allocated to warrant liabilities----604,118-
Change in fair value of derivative liabilities----5-15,144,986
Change in fair value of accrued issuable equity----9,405-
Prepaid expenses and other current assets---210,1951-1,018,303
Accounts payable---2-5,730,5371
Accrued expenses----9,405-1,646,657319,936
Accrued expenses – related parties-----169,788
Accrued issuable equity----52,500-
Total adjustments---8953,22027
Net Cash Used In Operating Activities-497,357-789,230-1,452,235-3,871,961-19,371,428-12,127,585
Offering costs in connection with July 2022 sale of common stock and common stock warrants------529,982
Offering costs in connection with December 2022 sale of common stock and common stock warrants-----2,055,130-484,991
Proceeds from loans payable---82,500-1
Repayment of convertible debt – related parties--209,415-10,000-
Repayment of loans payable, net of adjustments (Note 9)---72,843807,5942
Repayment of loans payable – related parties61,558200,000100,000--81,277
Proceeds from sale of July 2022 common stock and common stock warrants---72,500276
Proceeds from sale of December 2022 common stock and common stock warrants-----6
Proceeds from exercise of July 2022 pre-funded warrants------263
Proceeds from exercise of December 2022 pre-funded warrants------150
Net Cash Provided By Financing Activities117156,844-106,508,638-2511
Effect of Exchange Rate Changes on Cash------419
Net (Decrease) Increase In Cash----6-1,254,398
Cash paid during the period for income taxes225,000-----
Cash paid during the period for interest----35,35115,060
Common stock issued upon conversion of KBL debt----2-
Common stock issued upon conversion of 180 debt----432,383-
Common stock issued in connection with repayment of related party loans and convertible notes---223,710--
Shares and warrants issued for Alpha Settlement----1-
Exchange of common stock equivalents for common stock----146-
Shares issued to settle accounts payable----2-
Reclassification of accrued issuable equity----43,095-